Hixs and Hers (HISS) Q2 revenue 2025

Stock Hixs and health Dropped from 9% in extended trading on Monday.

The company is based on the assessment of the average analysts developed by LSEG here:

• Profit per share: 17 cents, 15 cents are expected
• Income: 544.8 mln. $ 552 million expected

In the former quarter, their revenue increased by 73%, at the same period last year 315.6 mln. Dollars, which is on issue. Hixs and HESS reported 6 cents a year earlier per year, including $ 42.5 million or one share per share or per share per share or per share.

In the third quarter, HISS and HERs were $ 570 million and $ 590 million, and analysts said they waited $ 583 million. The company assumed that its adjusted benefit interests, taxes, depreciation and depreciation or eBitda, $ 70 million in the quitter. Streetalcount questionnaire is 77.1 million dollars.

Hiss & Hers resisted suffering in recent months GLP-1SIt’s cheap, the blockbuster is a drug for diabetes and weight loss. Captured drugs may be released from embossed drugs flawBut the US Department of Food and Drug Published The delivery issues were resolved in February.

Some telecommunications companies, including HISS and HERS, offered medicines. This is legal that if they are unique to the doses of knockouts, such as allergies to the ingredient in the brand in the brand product. HISS and HERS said If consumers are used clinically, they can access individual dosage through its website.

In June, more than 30% compared to their shares and branches A short-lived cooperation together Novo nordisk fell down. The drug officer said that the prosperity to say “Legal to prohibit the mass sale of false medicines” and said “failed to follow the law.”

The EBESS and HERs reported in the second quarter amounted to $ 82 million in the second quarter and 39.3 mln. Dollars and street accounts reported as more than 73 million dollars.

Hixs and Hers are posting its quarterly address at 5 to investors.

– CNBC’s Anka Kim Konstantino contributed to this report.